Compare Cassava Sciences Inc (FLNA) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Southwest Airlines Co — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Southwest Airlines Co trades at $49.8 (market cap $24.07B). The key difference: Southwest Airlines Co is far larger — about 453× Cassava Sciences Inc's market cap, and Southwest Airlines Co pays a 1.46% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | LUV | |
|---|---|---|
Market Cap | $53.14M | $24.07B |
Sector | Health | Industrials |
52-Week High | $4.64 | $54.80 |
52-Week Low | $1.09 | $29.06 |
Enterprise Value | -$33.43M | $27.14B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Southwest Airlines (LUV) trades at $47.56, down 0.75% on the day, with a mixed technical picture showing bullish signals from moving averages and oscillators but near-term support at $47. Fundamentally, the company reported revenue of $28.06B for 2025 with a net income margin of 2.83%, though earnings missed expectations in Q1 2026. Recent news highlights upcoming Q2 2026 earnings on July 23, 2026, with analysts focused on travel demand and fuel cost pressures.
The investment outlook balances transformation initiatives and resilient travel demand against significant fuel price volatility and execution risks. Analyst consensus is mixed with a $52.47 price target, representing ~10% upside, but risks include lack of fuel hedging and competitive pressures. The stock's valuation at a P/E of 32.83 appears elevated relative to historical airline multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
